ClinicalTrials.gg
CompletedNCT03730831NETPSYCHUpdated Aug 13, 2024

Childhood Maltreatment, Traumatic Experiences and Stress-associated Parameters in Schizophrenia Spectrum Disorders

An interventional study of Narrative Exposure Therapy in Schizophrenia Spectrum Disorder and PTSD, sponsored by University of Konstanz. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by University of Konstanz · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jan 2018, registered Jul 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Childhood maltreatment (CM) in psychotic disorders is associated with increased cognitive deficits, severe psychotic symptoms, and increased comorbidity. The number of different stress experiences also increases the probability of trauma-associated symptoms. Furthermore, neurobiological changes play a key role in the vulnerability of individuals with early traumas for mental and physical illnesses, among others for diseases of the schizophrenia spectrum disorder and the further course of the disease.

The project is divided into two work programs and pursues:

  1. A detailed recording of the course of symptoms in participants with schizophrenia spectrum disorder to link this data with a systematic recording of CM and traumatic experiences and biological data.
  2. On a subsample of participants with schizophrenia spectrum disorder and a comorbid post-traumatic stress disorder (PTSD), the researchers want to investigate whether symptom traits of existing psychotic disorders, trauma-associated symptoms and cognitive functions can be influenced by a trauma-specific treatment (NET), that has been proven to be effective in the treatment of PTSD.
Read the detailed description

Numerous scientific findings point to the influence of CM and traumatic experiences on the risk of mental and physical illnesses, their severity and their course. Traumatic experiences also increase the risk of demonstrating psychotic symptoms or even develop psychotic disorders. Furthermore, the number of different stress experiences also increases the probability of trauma-associated symptoms (symptoms of post-traumatic stress disorder (PTSD) and dissociative experiences).

Neurobiological changes in the immune system, the defense of stress and also central nervous circuits and structures play a key role in the vulnerability of individuals with early traumas for mental and physical illnesses, e.g. for diseases of the schizophrenia spectrum disorder and the further course of the disease.

The recording of stressful and traumatic life experiences has been largely neglected in everyday clinical practice, especially in patients with a schizophrenia spectrum disorder. The diagnosis of PTSD is rarely given in everyday clinical practice, so that trauma-specific treatment is often not offered.

The targeted use of a scientifically proven intervention to reduce the symptoms of PTSD (NET: Narrative Exposure Therapy) involves a change in stress-associated biomolecular parameters and normalizes neuronal brain activity.

The project pursues a systematic assessment of CM and traumatic experiences as well as a detailed recording of the course of symptoms in participants with schizophrenia spectrum disorder. Furthermore, in a subsample of participants with schizophrenia spectrum disorder and comorbid PTSD, the researchers want to investigate whether symptom traits of existing psychotic disorders, trauma-associated parameters and cognitive functions can be influenced by a trauma-specific treatment (NET).

The original research plan had to be modified because of the COVID-19 restrictions. Thus, during the course of the study, we had to modify design and data assessment.

The original plans related to the two work programs of the study and their modification are described below:

Work program 1 (WP1):

Originally, the WP1 included a weekly prospective assessment of psychotic symptoms on a sample of n=100 participants with schizophrenia spectrum disorder and planed to link this data with results from a cross-sectional assessment on traumatic and childhood maltreatment and biological data (cortisol awakening (CAR), diurnal cortisol profile, tonic cortisol concentration in hair and determination of mitochondrial respiratory activity in mononuclear cells).

Modifications of the original study plan of WP1:

  1. Originally, it was planned to examine the determination of mitochondrial respiratory activity in mononuclear cells. Due to a change in cooperation with a partner study project, examination of mitochondrial respiratory activity in mononuclear cells was later on excluded and focus was set only on the endocrine system via cortisol response (CAR, diurnal cortisol profiles and hair cortisol concentration).
  2. Due to the COVID pandemic, saliva samples could only be collected before pandemic restriction rules. Therefore, not all participants contributed in all parts of the originally planned WP1.
  3. Due to COVID restrictions, access to the study population was restricted and the planned total of n=100 could not be completed, instead n=79 patients could be included into the study.
  4. In addition to the patient data, we also collected data from healthy controls (n=39) to replicate existing findings between healthy controls and people with schizophrenia spectrum disorder.
  5. In addition to the clinical interview (cross-sectional assessment) of traumatic and childhood maltreatment, we included measurements of parental bonding (high/low parental care, high/low overprotection) to have a more detailed look on how childhood experiences can influence symptom course of psychotic disorders.
  6. The weekly assessment of psychotic symptoms did not proof to be feasible in daily clinical routine due to the high time consumption of assessments during COVID restrictions. Outcome measures therefore focused on three points in time, i.e. admission to study, 4 weeks after admission, and 3 months after admission or - if released earlier - at release from inpatient treatment.

The adapted WP1 pursued the following research questions:

  1. What influence do childhood maltreatment and traumatic experiences have on current psychological and physical well-being (systematic \& detailed symptom recording)?
  2. What influence does the family atmosphere have on the illness course?
  3. Do parameters of the stress hormone system (wake-up cortisol, diurnal cortisol profile, hair cortisol concentration) correlate with measures of past childhood maltreatment, traumatic experiences, and parental bonding?

    Work program 2 (WP2):

    The second work program originally focussed on the subgroup of WP1 participants with schiziphrenia spectrum disorder and comorbid PTSD. It was planned to conduct a randomized controlled pilot study with n=20 to determine the impact of trauma-focused therapy (NET) on the course of symptoms. In addition to the symptoms of PTSD, psychosis-specific parameters such as cognitive functions and biological characteristics were planned to be repeatedly recorded (pre, post, 6 months and 12 months after completing trauma therapy).

    Modifications of the original study plan of WP2:

    1. Originally, a randomized control pilot study was planned with n=20 participants randomly allocated to either an active intervention group (n=10, receiving NET additionally to care as usual) or to a no treatment group (care as usual; n=10). Due to restricted manpower and lowered feasibility in clinical daily routine during COVID, our study design had to be adapted and the control group had to be omitted. In stead, we conducted a case series of the 10 cases who received the active treatment. The adapted study, therefore, had a single-group, pre-test, post-test, and follow-up-test design.
    2. We planned to implement 6-10 trauma therapy sessions of 90 minutes per case. Due to the specific nature of psychotic disorders (e.g., conceptual disorganization or limited cognitive capacities), the NET routine had to be adapted. For example, the length of the sessions often had to be shortened, which led in most cases to a higher number of sessions as planned (on average 15-20 sessions). For more details, see our publication: Breinlinger, S., Pütz, A.-K., Stevens, N. R., Mier, D., Schalinski, I., \& Odenwald, M. (2020). Narrative Exposure Therapy in challenging cases and conditions. Maltrattamento e Abuso All'Infanzia: Rivista Interdisciplinare, 22(3), 37-50. https://doi.org/10.3280/MAL2020-003004.
    3. Furthermore, the follow-up assessment was changed to only pre (T0), post (T1) and 6 month follow-up (T2, 6 months after completing NET) for all measurements (PTSD symptoms, dissociation, cognitive functions, psychotic symptoms, depression, suicidal tendencies, quality of life).
    4. In the longitudibal course of WP2, biological data were only assessed at T1 (see reasons above relating to COVID pandemic). Instead, focus was set on clinical parameters: Primary outcomes were diagnosis, symptom severity of PTSD and dissociation assessed at T0, T1 and T2. Secondary outcomes were depressive symptoms, psychotic symptoms, suicidal tendencies, quality of life and cognitive performance measured by a standardized test battery. Single t-tests were used for data analysis.

    WP2 therefore pursued the following research questions:

  4. What changes of trauma-related and psychotic symptoms can be observed in patients with schizophrenia spectrum disorder and PTSD after a specific PTSD treatment module?

Giving the division of the work program in a cross sectional and a prospective part, our original study title "Narrative Exposure Therapy in Patients With Psychotic Disorders and a Posttraumatic Stress Disorder" included only WP2. In order to place both work programs in an overall context, the overall title was changed to:

"Childhood maltreatment, traumatic experiences and stress-associated parameters: Relationship and influence on the course of illness in schizophrenia spectrum disorders."

02

Conditions studied

  • Schizophrenia Spectrum Disorder
  • PTSD

Keywords

  • Course
  • Schizophrenia Spectrum Disorder
  • Posttraumatic Stress Disorder
  • Narrative Exposure Therapy
03

In context

Stress Disorders, Post-Traumatic

2,682 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 601 are open to participants now.

This study's enrollment of 10 is below the median of 69 across 2,196 interventional studies indexed under Stress Disorders, Post-Traumatic.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

University of Konstanz is the lead sponsor of 51 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for the first work program:

  • Patients with schizophrenia spectrum disorder

Inclusion Criteria for the second work program:

  • Patients with schizophrenia spectrum disorder and comorbid PTSD Diagnosis ()

Exclusion Criteria (1st and 2nd work program):

  • mental impairment (e.g. dementia)
  • insufficient language comprehension
  • non-compliance with appointments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Intervention (second work program)

    Narrative Exposure Therapy Narrative Exposure Therapy (NET) is a brief manualized trauma-focussed psychotherapeutic treatment and will be performed according to the manual of Schauer et al., 2011. In NET, traumatic experiences are worked through and placed in the context of the entire life story.

    Behavioral: Narrative Exposure Therapy

Interventions

  • BehavioralNarrative Exposure Therapy

    8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling -\> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder.

06

What researchers measure

Primary outcomes

  1. PTSD symptom severity (PCL-5)

    PTSD symptoms are measured in interview process (reporting period: previous 4 weeks) with the PTSD Checklist - 5 (PCL-5; Weathers, Litz, et al., 2013).

    Time frame: 1st. work program: at baseline. 2nd work program: Change from baseline (T0) to post treatment (T1; 1 week after completing NET) and 6-month follow-up (T2, 6 months after completing NET)

  2. Psychotic Symptom Severity

    The course of psychotic symptoms is measured during inpatient treatment (from admission to study to release from inpatient treatment, typically for 6-8 weeks) with the Positive and Negative Syndrome Scale (PANSS; Kay, S. R., Fiszbein, A., \& Opfer, L. A. (1987).

    Time frame: 1st workprogram: Change from admission to 4 weeks and 3 months after admission or if earlier at release; 2nd workprogram: Change of psychotic symptoms from baseline (T0) to post (T1; 1 week after completingNET) and 6 months follow-up (T2)

  3. Dissociation (Shut-D)

    Dissociative symptoms are assessed using the Shutdown Dissociation Scale (Shut-D), which measures the frequency of symptoms such as fainting, blurred vision, dizziness, altered hearing or vision, numbness, paralysis, and others {Schalinski, 2015 #46}. Participants reported the frequency of these symptoms over the past 6 months on a scale from 0 (not at all) to 3 (several times a week), with a total score ranging from 0 to 39.

    Time frame: 1st. work program: at baseline. 2nd work program: Change from baseline (T0) to post-treatment (T1; 1 week after completing NET) and 6 months follow-up (T2; 6 months after completing NET)

  4. Childhood maltreatment including parental bonding/family atmosphere

    CM are assessed using the Maltreatment and Abuse Chronology of Exposure scale (MACE; {Teicher, 2015 #73}; German version KERF by {Isele, 2014 #44}) developed to retrospectively assess exposure to ten types of CM from infancy to age 18, encompassing abuse (such as physical, verbal, and non-verbal emotional abuse, witnessing interparental and sibling abuse, peer-related verbal abuse and physical bullying, and intra-, extra-familial, or peer-related sexual abuse) as well as emotional and physical neglect.

    Time frame: 1st and 2nd work program: at baseline.

  5. cortisol awakening response (CAR), diurnal cortisol profile and corresponding hair cortisol concentration

    During the first hour after awakening saliva samples will be repeatedly collected following the established procedure.

    Time frame: only 1st work program: CAR at awaking, 30, 45 and 60 minutes after awakening; at noon (directly before lunch) and in the evening (directly before dinner); Hair cortisol concentration once

Secondary outcomes

  1. MATRICS Consensus Cognitive Battery

    Cognitive change is measures with the MATRICS Consensus Cognitive Battery (Nuechterlein et al., 2008)

    Time frame: only 2nd work program: Change in cognitive functions is measured at baseline (T0), post-treatment (T1; within 1 month after completing NET) and 6 months follow-up (T2; 6 months after completing NET)

  2. Depression Severity

    Changes in depressive symptoms measured with Beck DEpression Inventory revised (BDI-II)

    Time frame: 1st. workprogram: at baseline. 2nd work program: Change in depression severity is measured at baseline (T0), post-treatment (T1; within 1 week after completing NET) and 6 months follow-up (T2; 6 months after completing NET)

  3. Suicidal tendenies

    MINI International Neuropsychiatric Interview (M.I.N.I.), Suicidal Scale (Lecrubier et al., 1997)

    Time frame: 1st. workprogram: at baseline. 2nd work program: Change in suicidal tendencies is measured at baseline (T0), post-treatment (T1; within 1 week after completing NET) and 6 months follow-up (T2; 6 months after competing NET)

  4. Changes in quality of life

    WHO Disability Assessment Schedule (WHODAS 2.0; World Health Organization, 2010)

    Time frame: 1st. workprogram: at baseline. 2nd work program: Change in quality of life is measured at baseline (T0), post-treatment (T1; within 1 week after completing NET) and 6 months follow-up (T2; 6 months after completing NET)

07

Study locations

1 site
  • University of Konstanz, Psychotherapy Outpatient Clinic
    Konstanz, 78464, Germany
08

References and documents

Publications

  • Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2. PubMed 18172019 ↗
  • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261. PubMed 3616518 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03730831
Lead sponsor
University of Konstanz
Collaborators
Centre for Psychiatry Reichenau
Responsible party
Michael Odenwald (Head of psychological outpatient clinic, head of psychology at the research ward, University of Konstanz) — Principal investigator
First posted
Nov 5, 2018
Start date
Jan 1, 2018
Primary completion
Oct 24, 2022
Completion
Oct 24, 2022
Last update
Aug 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion